-
Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety risk
Eli Lilly and Co. is seeking U.S. Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after the recently approved Leqembi from Japanese drugmaker Eisai.